Quantcast

Brain Tumor Patient Community Delivers Priorities to Congress: Invest in Research and Ensure Access to Oral Chemotherapy

May 8, 2012

As National Brain Tumor Awareness Month begins, the National Brain Tumor Society and Accelerate Brain Cancer Cure will rally staff, family members, patients and advocates to urge Members of Congress to increase funding for the National Institutes of Health (NIH) and support the Cancer Drug Coverage Parity Act (HR 2746) tomorrow. In a time of heated debate over the budget and significant changes to the healthcare system, the Group hopes to put a face to these issues and acquire the support of Congress to unite against brain tumors, one of the most deadly forms of cancer and one with very few approved medicines.

Washington, D.C. (PRWEB) May 07, 2012

As National Brain Tumor Awareness Month begins, the National Brain Tumor Society and Accelerate Brain Cancer Cure will rally staff, family members, patients and advocates to urge Members of Congress to increase funding for the National Institutes of Health (NIH) and support the Cancer Drug Coverage Parity Act (HR 2746) tomorrow. In a time of heated debate over the budget and significant changes to the healthcare system, the Group hopes to put a face to these issues and acquire the support of Congress to unite against brain tumors, one of the most deadly forms of cancer and one with very few approved medicines.

“An increasing number of brain tumor patients are reporting higher co-pays or co-insurance costs to access temozolomide, an oral chemotherapy medicine. Oral temozolomide is often part of the standard of care and is one of the few options — patients must have access to this medicine to stay alive,” said Paul TonThat, Executive Director, National Brain Tumor Society. “It´s unacceptable for obstacles in health insurance to exist which deter or prevent patients from accessing brain cancer medication,” concluded TonThat. The Cancer Drug Coverage Parity Act would require health insurance plans that already cover oral, IV and injectable chemotherapy to cover oral chemotherapy on an equal out-of-pocket cost basis as traditional IV and injectable chemotherapy.

Max Wallace, Chief Executive Officer, Accelerate Brain Cancer Cure addressed the need to increase funding for the National Institutes of Health by stating “Congress should really step up its support of NIH research, as funding is critical to accelerating discovery which can lead to new treatments for brain tumor patients. Science is developing so rapidly that any cuts can set back research progress by many years.”

BethAnn Telford, a brain tumor survivor said it best “We have to do better as a country to help patients survive and to find cures. Congress should do its part by ensuring access to oral chemotherapy and increased funding for the NIH.”

About National Brain Tumor Society (NBTS)

National Brain Tumor Society is fiercely committed to finding a cure for brain tumors. We aggressively drive strategic research, advocate for public policies that meet the critical needs of the brain tumor community, and provide patient information. National Brain Tumor Society is the largest brain tumor nonprofit organization in the country, hosting events, workshops, and scientific symposiums throughout the United States. For more information, visit http://www.braintumor.org.

About Accelerate Brain Cancer Cure (ABC2)

Accelerate Brain Cancer Cure is focused on speeding the discovery of a cure for brain cancer. By applying an aggressive, venture funding approach not typically seen in the nonprofit sector, ABC2 closes current gaps in funding in order to catalyze research and rapidly bring new therapies to patients. ABC2 invests in early-stage biotechnology companies and awards grants to renowned brain cancer researchers to drive collaborative projects which demonstrate leadership, leverage, and impact. For more information, visit http://www.abc2.org.

Contacts:

Alison Bengel

National Brain Tumor Society

abengel(at)braintumor(dot)org

617.393.2841

Nicola Beddow

Accelerate Brain Cancer Cure

nicola.beddow(at)abc2(dot)org

202.467.2051

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/5/prweb9474726.htm


Source: prweb



comments powered by Disqus